A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10830-10839

  Zhuang, Chunlin ^a   Sheng, Chunquan ^a   Shin, Woo Shik ^b   Wu, Yuelin ^a   Li, Jin ^a   Yao, Jianzhong ^a   Dong, Guoqiang ^a   Zhang, Wen ^a   Sham, Yuk Yin ^a,b   Miao, Zhenyuan ^a   Zhang, Wannian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

antitumor activity; Dual inhibitors; Enantiomer; Molecular dynamics; Molecular recognition; Nf b; P53 MDM2

Indexed keywords

5 [3 (1H IMIDAZOL 1 YL)PROPYL] 4 (4 BROMO PHENYL) 1 (4 FLUOROBENZYL ) 3 PHENYL 4,5 DIHYDROPYRROLO[3,4]PYRZOL 6(1H) ONE; ANTINEOPLASTIC AGENT; DOXORUBICIN; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53; PYRROLO[3,4 C]PYRAZOLE; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; 5-(3-(1H-IMIDAZOL-1-YL)PROPYL)-4-(4-BROMOPHENYL)-1-(4-FLUOROBENZYL)-3-PHENYL-4,5-DIHYDROPYRROLO(3,4-C)PYRAZOL-6(1H)-ONE; PYRAZOLE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENANTIOMER; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STEREOCHEMISTRY; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FLOW CYTOMETRY; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MDM2; PYRAZOLES; PYRROLIDINONES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916942995     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2521     Document Type: Article

References (28)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
2. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature reviews Cancer. 2002; 2:594-604.
3. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303:844-848.
4. Grasberger BL, Lu TB, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao SY, Ramachandren K, Bylebyl GR, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem. 2005; 48:909-912.
5. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding YS, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y, Parrish DA, Deschamps JR, Wang SM. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc. 2005; 127:10130-10131.
6. Rew Y, Sun D, Gonzalez-Lopez De Turiso F, Bartberger MD, Beck HP, Canon J, Chen A, Chow D, Deignan J, Fox BM, Gustin D, Huang X, Jiang M, Jiao X, Jin L, Kayser F, et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem. 2012; 55:4936-4954.
7. Pahl HL. Activators and target genes of Rel/NF-kappa B transcription factors. Oncogene. 1999; 18:6853-6866.
8. Chen LF, Greene WC. Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Bio. 2004; 5:392-401.
9. Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nature reviews Molecular cell biology. 2007; 8:49-62.
10. Garg A, Aggarwal BB. Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia. 2002; 16:1053-1068.
11. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. P53 stabilization is decreased upon NF kappa B activation: A role for NF kappa B in acquisition of resistance to chemotherapy. Cancer Cell. 2002; 1:493-503.
12. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappa B pathways. Nat Rev Drug Discov. 2008; 7:1031-1040.
13. Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert opinion on drug metabolism & toxicology. 2009; 5:921-931.
14. Roth BL. Drugs and valvular heart disease. The New England journal of medicine. 2007; 356:6-9.
15. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008; 321:263-266.
16. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nature reviews Cancer. 2010; 10:130-137.
17. Tang J, Maddali K, Dreis CD, Sham YY, Vince R, Pommier Y, Wang ZQ. N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. Acs Med Chem Lett. 2011; 2:63-67.
18. Chen LQ, Petrelli R, Gao GY, Wilson DJ, McLean GT, Jayaram HN, Sham YY, Pankiewicz KW. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorganic & Medicinal Chemistry. 2010; 18:5950-5964.
19. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012; 492:215-220.
20. Zhuang C, Miao Z, Zhu L, Dong G, Guo Z, Wang S, Zhang Y, Wu Y, Yao J, Sheng C, Zhang W. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. J Med Chem. 2012; 55:9630-9642.
21. Zhuang C, Miao Z, Wu Y, Guo Z, Li J, Yao J, Xing C, Sheng C, Zhang W. Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53-MDM2 Interaction and the NF-kappa B Pathway. J Med Chem. 2014; 57:567-577.
22. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88:323-331.
23. Raza A, Sham YY, Vince R. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. Bioorganic & Medicinal Chemistry Letters. 2008; 18: 5406-5410.
24. Maestro 9.3 G, Prime 3.1, Macromodel 9.9, Desmond 3.1; Schrodinger, LLC: New York, NY, 2012.
25. Xu GZ, Lo YC, Li QB, Napolitano G, Wu XF, Jiang XL, Dreano M, Karin M, Wu H. Crystal structure of inhibitor of kappa B kinase beta. Nature. 2011; 472: 325-U222.
26. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc. 1996; 118:11225-11236.
27. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983; 79: 926-935.
28. Research DES. (2008). Desmond Molecular Dynamics System. (New York, NY).